Looks at how well deucravacitinib works for plaque psoriasis in everyday care
Observes deucravacitinib's real-world effect in adults with moderate-to-severe plaque psoriasis.
Plain-language title generated from the registry record
Registry title: A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
Key facts
- Where
- La Chaux-de-Fonds, SwitzerlandSee the 3 sites
Where in Switzerland
- Cabinet MedicalLa Chaux-de-Fonds, SwitzerlandTaking people
- La Chaux-de-FondsLa Chaux-de-Fonds, SwitzerlandNo longer taking part
- La Chaux-de-FondsLa Chaux-de-Fonds, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06701513
- Record updated
- 18 May 2026
- Original description
The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasisRead full original descriptionShow less
Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-world, Prospective, Observational Study of the Effectiveness of Deucravacitinib in Adults With Moderate-to-Severe Plaque Psoriasis in France
The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis
Inclusion: ≥18 years of age; Physician-reported diagnosis of moderate to severe plaque psoriasis; Be newly initiating deucravacitinib; Do not object to participate.
Exclusion: Previous treatment experience with deucravacitinib, including patients who received deucravacitinib as part of a blinded, randomized trial; Currently participating in or planning to participate in an interventional clinical trial.